New Drug Promising Against Rheumatoid Arthritis

...ity Hospital for Joint Diseases, New York City, said that "for those patients who have failed or had an inadequate response to etanercept, infliximab, adalimumab or abatacept, golimumab might be a good option." The study, which was funded by drug makers Centocor, Inc. and Schering- Plough, appears online Jun...

AGA Institute presents cutting-edge research during DDW

...tients with Prior Non-response, Viral Breakthrough or Relapse to Peginterferon-Alfa-2a/b and Ribavirin Therapy. A.M. Di Bisceglie et al. (3:00 p.m.)* adalimumab Induces and Maintains Mucosal Healing in Patients With Moderate to Severe Ileocolonic Crohn's Disease First Results of the EXTEND Trial. P. Rutgeerts...

For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission

...g its approval for the indication in 2011. Interviewed experts believe that adalimumab has potential to be superior in maintenance of remission when compared to i..."Although clinical trial data are limited, interviewed experts believe that adalimumab will be more effective than infliximab in the maintenance setting and that ...

Rheumatoid Arthritis Drugs Raise Shingles Risk

...latest study, researchers from the German Rheumatism Research Centre in Berlin looked at 5,040 people taking the TNF blockers infliximab (Remicade) or adalimumab (Humira), the fusion protein etanercept (Enbrel) or the monotherapeutic drug anakinra (Kineret). Although generally considered a TNF blocker, Enbr...

Adalimumab may reduce health-care costs for Crohn's disease patients

...r our understanding of these major illnesses. adalimumab Therapy May Provide Important Economic Benefits fo...ts Crohn's disease (CD) patients treated with adalimumab have lower one-year risks of hospitalization and s...astroenterological Association (AGA) Institute. adalimumab is an anti-tumor necrosis factor (TNF) monoclonal ...

Rheumatoid Arthritis Treatment Guidelines Updated

...r patients with poor prognostic features and moderate to high levels of disease activity. Prescribing anti-TNF agents -- etanercept, infliximab, or adalimumab -- along with methotrexate in early RA (less than 3 months) only for patients with high disease activity who had never received DMARDs. In intermediat...

Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years

... remission of AS can have a considerable positive impact on a patient's symptoms. These data are reassuring for patients because they demonstrate that adalimumab can be an effective treatment for ankylosing spondylitis." Three-Year ATLAS Data Summary ATLAS was a randomized, placebo-controlled, double-blind,...

Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapies

... Paris, France, Thursday, 12 June 2008: adalimumab therapy is effective and well-tolerated in ankylos...tology in Paris, France. This positive response to adalimumab was greatest for patients who had been intolerant ... or infliximab. The results of our study show that adalimumab offers new hope for those who have tried, but not ...

50 percent of recent onset RA patients become free of signs and symptoms within 36 weeks

...ed at week 12, sulfasalazine was added (2grams/day) If not achieved at week 20, the dose was increased to 3grams/day If not achieved at week 24 adalimumab was added to methotrexate Every 3 months thereafter, therapy could be adjusted based on DAS28, also using other TNF-blockers. Patients were allowed...

American College of Rheumatology presents recommendations for rheumatoid arthritis therapy

... patients with poor prognostic features and moderate to high levels of disease activity. Prescribing anti-TNF agents -- etanercept, infliximab, or adalimumab -- along with methotrexate in early RA (less than 3 months) only for patients with high disease activity who had never received DMARDs. In intermedia...

Adalimumab in Medical Technology

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

...clonal antibody) on SIMPONI response. The occurrence of adverse events (AEs) through week 24 was similar among patients previously receiving only adalimumab (76 percent), etanercept (70 percent) and infliximab (78 percent), as well as among patients who received one, two and three prior anti-TNF-alpha agen...

CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients

...is for induction and maintenance dosing regimens for CIMZIA, infliximab and adalimumab was estimated for a 65kg patient over a two-year period. Response and remis... year 1 and 50 percent, 30 percent and 20 percent in year 2 for infliximab, adalimumab and CIMZIA, respectively, was performed for a healthcare plan of 5 million ...

New Genes Found for Inflammatory Bowel Disease in Children

...current treatments for IBD use monoclonal antibodies that selectively bind to a type of TNF involved in the disease (Among those drugs are infliximab, adalimumab and certolizumab). "As we better understand the complex gene interactions in IBD, we may be able to diagnose patients by their genetic profile to pred...

Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission

...bout the CHARM Trial The CHARM (Crohn's trial of the fully Human antibody adalimumab for Remission Maintenance) study enrolled 854 patients, both anti-TNF naive...one year compared to placebo. About the GAIN Trial In the GAIN (Gauging adalimumab effectiveness in Infliximab Nonresponders) study, a four-week induction tri...

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

...ients in the study. -- The modeled population PK analysis estimated a 59% maximal increase in the relative SC bioavailability of adalimumab at steady state if co-injected with rHuPH20; thus, the reported reference 64% SC absolute bioavailability HUMIRA injected alone was es...

Adalimumab in Biological News

Musculoskeletal center wins $2.2 million for drug safety

... of autoimmune disorders. Among the studied drugs is what's called anti-TNF agents, or anti-tumor necrosis factor alpha agents. This category includes adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade). Five additional biologics will be studied. The analysis will include patients who live in ...

New genes found for inflammatory bowel disease in children

...current treatments for IBD use monoclonal antibodies that selectively bind to a type of TNF involved in the disease (Among those drugs are infliximab, adalimumab and certolizumab). "As we better understand the complex gene interactions in IBD, we may be able to diagnose patients by their genetic profile to pred...

New guidelines for treating rheumatoid arthritis

...ents that leads to inflammation. Newer biologics called anti-TNF agents adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade) prevent the produc...ended for most RA patients. Anti-TNF agents etanercept, infliximab, or adalimumab along with methotrexate can be used in new or early RA cases with worsening...